Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 4/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5311034 | 0.92 | ALDH1A1 (0.58) | F10F2ALDH1A1PDE4APDE4B | |
| SCHEMBL6108930 | 0.91 | ALDH1A1 (0.55) | F10F2ALDH1A1SLC29A1PDE4A | |
| SCHEMBL5306322 | 0.90 | ALDH1A1 (0.54) | F10F2ALDH1A1SLC29A1PDE4A | |
| SCHEMBL15731769 | 0.90 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL5307046 | 0.90 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL6108800 | 0.89 | ALDH1A1 (0.52) | F10F2ALDH1A1PDE4APDE4B | |
| SCHEMBL3873568 | 0.87 | F10 (0.69) | F10F2SLC29A1 | |
| SCHEMBL6108195 | 0.87 | ALDH1A1 (0.51) | F10F2ALDH1A1PDE4APDE4B | |
| SCHEMBL1997488 | 0.87 | ALDH1A1 (0.51) | F10F2ALDH1A1PDE4APDE4B | |
| SCHEMBL16948138 | 0.87 | F10 (0.64) | F10F2SLC29A1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805179-A2 | PREPARATION OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | Brystol-Myers Squibb Company (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006135425-A2 | PREPARATION OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060069085-A1 | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069085-A1 | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | F2, TFPI, TFPI2 | F10 28/4885F2 1/4885ALDH1A1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.